-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Medical notifies availability of press release on Alpha DaRT-pembrolizumab head and neck cancer data

PUBT·07/21/2026 12:31:52
Listen to the news
Alpha Tau Medical notifies availability of press release on Alpha DaRT-pembrolizumab head and neck cancer data
  • Alpha Tau posted a new release on Alpha DaRT with pembrolizumab in locally advanced or metastatic head and neck cancer.
  • Nine evaluable patients showed 100% objective response rate; 4 complete responses.
  • Median overall survival was 18.2 months; median progression-free survival was 5.4 months.
  • No Alpha DaRT-related serious adverse events; 2 Grade 1 adverse events reported.
  • Full release: link.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210830PRIMZONEFULLFEED9765317) on July 21, 2026, and is solely responsible for the information contained therein.